Fig. 1From: Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trialTrough immunoglobulin G levels after 9 months of Hizentra injections. Trough IgG levels at follow-up were <5 g/L in 2 patients (2.1 % of patients) and ≥10 g/L in 28 patients (29.5 % of patients). Data were available for 95 patients with primary or secondary immunodeficienciesBack to article page